类风湿关节炎合并焦磷酸钙沉积病患者的特征与长期结局
基于美国退伍军人RA注册研究,2771例RA患者中64例(2.3%)合并CPPD。合并CPPD者年龄更大、合并症更多、ACPA阳性率更低。在血清阴性患者中,合并CPPD者泼尼松使用和b/tsDMARDs启动更频繁,关节置换和死亡发生率更高。
要点
- RA合并CPPD患者年龄更大、合并症更多、ACPA阳性率更低。
- 血清阴性RA合并CPPD者泼尼松使用和b/tsDMARDs启动更频繁。
- 血清阴性RA合并CPPD者关节置换和死亡发生率更高。
核心结论
- 血清阴性RA合并CPPD患者更频繁更换治疗、使用更多泼尼松且长期结局更差。
- 部分血清阴性RA可能实为CPPD,需要替代诊断和治疗策略。
研究设计与样本
- 基于美国退伍军人事务部RA注册(VARA)的队列研究,纳入2771例RA患者。
- 通过行政编码识别合并CPPD的患者,比较其与单纯RA患者的特征和长期结局。
主要发现
- 入组时64例(2.3%)合并CPPD,CPPD患者年龄更大[68.5(9.0)岁 vs 64.2(11.0)岁,p<0.001]。
- CPPD患者骨关节炎比例更高(93.8% vs 80.1%,p=0.007),ACPA阳性率更低(63.5% vs 77.8%,p=0.01)。
- CPPD患者达到低疾病活动度的可能性数值上更低,但无统计学显著性。
- 血清阴性患者中,CPPD患者泼尼松使用更多(OR 2.44 [95% CI 1.15-5.22]),b/tsDMARDs启动更频繁(OR 2.79 [95% CI 1.46-5.32])。
- 血清阴性CPPD患者随访期间关节置换和死亡发生率更高。
临床怎么用
- 对血清阴性RA患者应警惕合并CPPD的可能,考虑进行晶体相关检查。
- 合并CPPD的血清阴性RA患者可能需要更密切监测疾病活动和调整治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the characteristics, treatment patterns, and long-term outcomes of patients with concurrent calcium pyrophosphate deposition disease (CPPD) and rheumatoid arthritis (RA) to patients with RA without CPPD. METHODS: We studied patients with RA from the Veteran's Affairs RA (VARA) registry and identified patients with CPPD using administrative codes. We compared characteristics of patients with concurrent CPPD and RA to those with RA alone at enrollment. We used parsimonious multivariable logistic regression to study the probability of achieving a low disease activity as well as receiving prednisone and new biologic or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) over follow-up, adjusting for pre-hypothesized confounders and stratifying by autoantibody status. RESULTS: Among 2771 U.S. veterans with RA, we identified 64 (2.3 %) patients with CPPD at enrollment. Patients with CPPD were older [68.5 (9.0) v. 64.2 (11.0), p < 0.001], had higher rates of comorbidities, including osteoarthritis (93.8 % v. 80.1 %, p = 0.007), spine disease, and diabetes, and were less likely to have ACPA (63.5 % v. 77.8 %, p = 0.01). While those with CPPD were numerically less likely to achieve low disease activity over time, this was not statistically significant. Among seronegative patients, CPPD patients exhibited more prednisone use (OR 2.44 [95 % CI 1.15-5.22]) and more frequent initiation of b/tsDMARDs (OR 2.79 [95 % CI 1.46-5.32]) as well as higher rates of joint replacement and death during follow-up. CONCLUSIONS: Seronegative RA patients with CPPD changed therapies more frequently, used more prednisone, and had worse long-term outcomes. These findings suggest some seronegative RA may represent CPPD and require alternative diagnostic and treatment approaches.
引用
- Schanzer N, England BR, Wysham KD, et al. Characteristics and long-term outcomes of patients with rheumatoid arthritis and concurrent calcium pyrophosphate deposition disease. Semin Arthritis Rheum. 2025. PMID: 41485342. doi:10.1016/j.semarthrit.2025.152902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。